国药BBIBP-CorV疫苗在预防感染疫苗接种者住院和死亡中的效果:阿拉伯联合酋长国阿布扎比酋长国的回顾性研究结果
本研究基于阿布扎比酋长国2020年9月1日至2021年5月1日报告的214940例PCR阳性COVID-19病例,纳入176640例≥15岁且记录链接到疫苗接种状态的个体,回顾性观察BBIBP-CorV灭活疫苗的真实世界效果。结果显示,完全接种组预防COVID-19相关住院、重症监护住院和死亡的疫苗有效性分别为80%、92%和97%;部分接种组对住院无保护作用,对死亡有保护作用但无统计学意义。
要点
- 完全接种BBIBP-CorV对COVID-19相关住院、重症监护住院和死亡的有效性分别为80%、92%和97%。
- 部分接种组对重症和非重症监护住院均未观察到保护作用。
- 部分接种组对死亡有保护作用,但无统计学意义。
核心结论
- 在COVID-19大流行期间,使用国药BBIBP-CorV灭活疫苗的两剂方案可有效预防重症疾病和死亡。
- 单剂接种缺乏保护作用可能由血清转化和/或中和抗体反应不足、行为因素(即虚假保护感)和/或其他生物学因素(变异株出现、再感染可能性、疫苗保护持续时间等)解释。
研究设计与样本
- 这是一项基于社区的回顾性观察性研究,旨在确定BBIBP-CorV灭活疫苗在真实世界中预防住院和死亡的有效性。
- 研究参与者选自2020年9月1日至2021年5月1日期间向阿拉伯联合酋长国阿布扎比酋长国卫生部报告的214940例PCR阳性COVID-19病例。
- 纳入176640例年龄≥15岁、COVID-19阳性确诊且记录链接到疫苗接种状态的个体;记录不完整或缺失者被排除(n=38300)。
- 研究参与者根据疫苗接种状态分为三组:完全接种(两剂)、部分接种(单剂)和未接种。
- 研究结局包括COVID-19相关的综合医院和重症监护病房住院以及死亡;每种结局的疫苗有效性基于每1000人年的发病密度。
主要发现
- 完全接种组、部分接种组和未接种组分别包括62931、21768和91941人。
- 基于发病率比,与未接种组相比,完全接种个体预防COVID-19相关住院、重症监护住院和死亡的疫苗有效性分别为80%、92%和97%。
- 部分接种组对重症和非重症监护住院均未观察到保护作用,而对死亡有一些保护作用,但无统计学意义。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This is a community-based, retrospective, observational study conducted to determine effectiveness of the BBIBP-CorV inactivated vaccine in the real-world setting against hospital admissions and death. STUDY DESIGN: Study participants were selected from 214,940 PCR-positive cases of COVID-19 reported to the Department of Health, Abu Dhabi Emirate, United Arab Emirates (UAE) between September 01, 2020 and May 1, 2021. Of these, 176,640 individuals were included in the study who were aged ≥ 15 years with confirmed COVID-19 positive status who had records linked to their vaccination status. Those with incomplete or missing records were excluded (n = 38,300). Study participants were divided into three groups depending upon their vaccination status: fully vaccinated (two doses), partially vaccinated (single dose), and non-vaccinated. Study outcomes included COVID-19-related admissions to hospital general and critical care wards and death. Vaccine effectiveness for each outcome was based on the incidence density per 1000 person-years. RESULTS: The fully-, partially- and non-vaccinated groups included 62,931, 21,768 and 91,941 individuals, respectively. Based on the incidence rate ratios, the vaccine effectiveness in fully vaccinated individuals was 80%, 92%, and 97% in preventing COVID-19-related hospital admissions, critical care admissions, and death, respectively, when compared to the non-vaccinated group. No protection was observed for critical and non-critical care hospital admissions for the partially vaccinated group, while some protection against death was apparent, although statistically insignificant. CONCLUSIONS: In a COVID-19 pandemic, use of the Sinopharm BBIBP-CorV inactivated vaccine is effective in preventing severe disease and death in a two-dose regimen. Lack of protection with the single dose may be explained by insufficient seroconversion and/or neutralizing antibody responses, behavioral factors (i.e., false sense of protection), and/or other biological factors (emergence of variants, possibility of reinfection, duration of vaccine protection, etc.).
引用
- Ismail AlHosani F, Eduardo Stanciole A, Aden B, et al. Impact of the Sinopharm's BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE). Vaccine. 2022. PMID: 35193793. doi:10.1016/j.vaccine.2022.02.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。